Windtree Therapeutics Regains Compliance With Nasdaq
Windtree Therapeutics Regains Compliance With Nasdaq
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
專注於推進危重病症和疾病早期和晚期創新療法的生物技術公司Windtree Therapeutics, Inc.（“Windtree” 或 “公司”）（納斯達克股票代碼：WINT）今天宣佈，它已收到納斯達克股票市場有限責任公司（“納斯達克”）的投標價格合規信，通知Windtree已恢復遵守納斯達克上市規則5550（a）（2）下的最低出價要求，可以繼續在納斯達克資本市場上市。
The Company was previously notified by Nasdaq on January 22, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days, as required by the Nasdaq Listing Rules. To regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on May 3, 2024, the tenth consecutive trading day of the Company's common stock bid price closing above $1.00.
納斯達克此前曾於2024年1月22日通知該公司，該公司未遵守最低出價規則，因爲其普通股未能按照《納斯達克上市規則》的要求連續30個交易日達到1.00美元或以上的收盤價。爲了重新遵守該規則，公司必須至少連續10個交易日將最低收盤價維持在1.00美元或以上。該要求於2024年5月3日得到滿足，這是公司普通股買入價連續第十個交易日收於1.00美元以上。
譯文內容由第三人軟體翻譯。